22-Jan-2025 7:00 AM CST - Business Wire AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin
13-Jan-2025 7:00 AM CST - Business Wire AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Pr
23-Dec-2024 7:00 AM CST - Business Wire AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCures management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio
20-Nov-2024 7:00 AM CST - Business Wire AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference. AtriCures management is scheduled to participate in a fireside discussion on Wednesday, December 4, 2024, at 9:00 am Eastern Standard Time. Interested p
7-Nov-2024 7:00 AM CST - Business Wire AtriCure to Participate in the Stifel 2024 Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference. AtriCures management is scheduled to participate in a fireside chat on Monday, November 18, 2024, at 9:10 am Eastern Standard Time. Interested parties may access a li
29-Oct-2024 3:01 PM CST - Business Wire AtriCure Reports Third Quarter 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business, said Michael Carrel, President and Chief Executive Officer at AtriCure. During the quarter, we launched sev
28-Oct-2024 7:00 AM CST - Business Wire AtriCure to Participate in the UBS Global Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference. AtriCures management is scheduled to participate in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. Interested parties may access a li
8-Oct-2024 7:00 AM CST - Business Wire AtriCure to Announce Third Quarter 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in
Latest ATRC Trades by Congress Members
19-JUL-2024 - Josh Gottheimer, NJ (District 5) purchased between $1,001 and $15,000.
22-Jan-2025 7:00 AM CST - Business Wire AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin
13-Jan-2025 7:00 AM CST - Business Wire AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Pr
23-Dec-2024 7:00 AM CST - Business Wire AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCures management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio
20-Nov-2024 7:00 AM CST - Business Wire AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference. AtriCures management is scheduled to participate in a fireside discussion on Wednesday, December 4, 2024, at 9:00 am Eastern Standard Time. Interested p
7-Nov-2024 7:00 AM CST - Business Wire AtriCure to Participate in the Stifel 2024 Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference. AtriCures management is scheduled to participate in a fireside chat on Monday, November 18, 2024, at 9:10 am Eastern Standard Time. Interested parties may access a li
29-Oct-2024 3:01 PM CST - Business Wire AtriCure Reports Third Quarter 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business, said Michael Carrel, President and Chief Executive Officer at AtriCure. During the quarter, we launched sev
28-Oct-2024 7:00 AM CST - Business Wire AtriCure to Participate in the UBS Global Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference. AtriCures management is scheduled to participate in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. Interested parties may access a li
8-Oct-2024 7:00 AM CST - Business Wire AtriCure to Announce Third Quarter 2024 Financial Results AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in